• Current Ulcerative Colitis Treatment Strategy in Children 
en To content

Current Ulcerative Colitis Treatment Strategy in Children 


SOVREMENNAYA PEDIATRIYA.2015.5(69):81-87; doi10.15574/SP.2015.69.81 

Current Ulcerative Colitis Treatment Strategy in Children 

Berezenko V. S., Tkalyk O. M., Dyba M. B., Myhaylyuk H. Z.

SI «Institute of Pediatrics, Obstetrics and Gynecology, NAMS of Ukraine», Kiev, Ukraine 

The article deals with current ulcerative colitis treatment strategy in children according to the consensus guidelines of ECCO and ESPGHAN (2012). It presents the step-by-step algorithm of ulcerative colitis therapy according to NICE (National Institute for Health and Clinical Excellence, UK, 2013) guidelines.

Key words: ulcerative colitis, children, treatment, ECCO, ESPGHAN, NICE. 


1. Клиническая диетология детского возраста. Под ред. ТЭ Боровик, КС Ладодо. Москва. 2008: 608.

2. Baudet A, Colombel JF, Cortot A et al. 2010. A fulminant colitis index greater or equal to 8 is not predictive of colectomy risk in infliximab-treated moderate-to-severe ulcerative colitis attacks. Gastroenterologie Clinique Et Biologique. 34(11): 612—617. http://dx.doi.org/10.1016/j.gcb.2010.07.013; PMid:20832218

3. Khan KJ, Ullman TA, Ford AC et al. 2011. Antibiotic therapy in inflammatory bowel disease: a systematic review and meta-analysis. Am J Gastroenterol. 106: 661—673. http://dx.doi.org/10.1038/ajg.2011.64http://dx.doi.org/10.1038/ajg.2011.131http://dx.doi.org/10.1038/ajg.2011.72; PMid:21407187

4. Turner D, Hyams J, Markowitz J et al. 2009. Appraisal of the Pediatric Ulcerative Colitis Activity Index (PUCAI). Inflamm Bowel Dis. 15: 1218—1223. http://dx.doi.org/10.1002/ibd.20867; PMid:19161178

5. Timmer A, McDonald JWD, Tsoulis DJ et al. 2012. Azathioprine and 6_mercaptopurine for maintenance of remission in ulcerative colitis. Cochrane Database of Systematic Reviews. —— Issue 9: CD000478. http://dx.doi.org/10.1002/14651858.CD000478.pub3.

6. Biancone L, Gionchetti P, Blanco GDV et al. 2007. Beclomethasone dipropionate versus mesalazine in distal ulcerative colitis: A multicenter, randomized, doubleblind study. Digestive and Liver Disease. 39(4): 329—337. http://dx.doi.org/10.1016/j.dld.2007.01.012; PMid:17347061

7. Burisch J, Munkholm P. 2013. Inflammatory bowel disease epidemiology. Current Opinionin Gastroenterology. 29(4): 357—362. [PubMed] http://dx.doi.org/10.1097/MOG.0b013e32836229fb; PMid:23695429

8. Chande N, MacDonald JK, McDonald JWD. 2007. Methotrexate for induction of remission in ulcerative colitis. Cochrane Database of Systematic Reviews. Issue 4:CD006618. http://dx.doi.org/10.1002/14651858.CD006618.pub2

9. Branche J, Cortot A, Bourreille A et al. 2009. Cyclosporine treatment of steroid_refractory ulcerative colitis during pregnancy. Inflammatory Bowel Diseases. 15(7): 1044—1048. http://dx.doi.org/10.1002/ibd.20858; PMid:19137604

10. Halmos EP, Gibson PR. 2012. Dietary management of IBD-insights and advice Nature Reviews. Gastroenterology & Hepatology: 133—146 (2015) http://dx.doi.org/10.1038/nrgastro.2015.11; PMid:25645969

11. Van Limbergen J, Russell RK, Drummond HE et al. 2008. Difinition of phenotypic caracteristics of children-onset inflammatory bowel disease. Gastroenterology. 57: 331—385.

12. Van Limbergen J, Russell RK, Drummond HE et al. 2008. Difinition of phenotypic characteristics of childhood-onset inflammatory bowel disease. Gastroenterology. 135: 1114-1122. http://dx.doi.org/10.1053/j.gastro.2008.06.081; PMid:18725221

13. Miele E, Pascarella F, Giannetti E et al. 2009. Effect of a probiotic preparation (VSL-3) on induction and maintenance of remission in children with ulcerative colitis. Am J Gastroenterol. 104: 437—443. http://dx.doi.org/10.1038/ajg.2008.118; PMid:19174792

14. Heyman MB, Kierkus J, Spenard J et al. 2010. Efficacy and safety of mesalamine suppositories for treatment of ulcerative proctitis in children and adolescents. Inflamm Bowel Dis. 16: 19. http://dx.doi.org/10.1002/ibd.21256; PMid:20848454 PMCid:PMC3252049

15. Ford AC, Achkar JP, Khan KJ et al. 2011. Efficacy of 5-aminosalicylates in ulcerative colitis: systematic review and meta-analysis. Am J Gastroenterol. 106: 601—616. http://dx.doi.org/10.1038/ajg.2011.67http://dx.doi.org/10.1038/ajg.2011.71

16. Khan KJ, Dubinsky MC, Ford AC et al. 2011. Efficacy of immunosuppressive therapy for inflammatory bowel disease: a systematic review and meta-analysis. Am J Gastroenterol. 106: 630—642. http://dx.doi.org/10.1038/ajg.2011.64http://dx.doi.org/10.1038/ajg.2011.131http://dx.doi.org/10.1038/ajg.2011.72

17. Zocco MA, dal Verme LZ, Cremonini F et al. 2006. Efficacy of Lactobacillus GG in maintaining remission of ulcerative colitis. Aliment Pharmacol Ther. 23: 1567—1574. http://dx.doi.org/10.1111/j.1365-2036.2006.02927.x; PMid:16696804

18. Ford AC, Khan KJ, Sandborn WJ et al. 2012. Efficacy of topical 5-aminosalicylates in preventing relapse of quiescent ulcerative colitis: a meta-analysis. Clin Gastroenterol Hepatol. 10: 513—519. http://dx.doi.org/10.1016/j.cgh.2011.10.043; PMid:22083024

19. Benchimol EI, Fortinsky KJ, Gozdyra P et al. 2011. Epidemiology of pediatric inflammatory bowel disease: a systematic review of international trends. Inflamm Bowel Dis. 17: 423—39. http://dx.doi.org/10.1002/ibd.21349; PMid:20564651

20. Rahier JF, Ben-Horin S, Chowers Y, Crohns J et al. 2009. European evidence-based Consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. Colitis. 3: 47—91. http://dx.doi.org/10.1016/j.crohns.2009.02.010; PMid:21172250

21. Glick SR, Carvalho RS. 2011. Inflammatory bowel disease. Pediatr Rev. 32: 14—24. http://dx.doi.org/10.1542/pir.32-1-14; PMid:21196502

22. Guslandi M, Giollo P, Testoni PA. 2003. A pilot trial of Saccharomyces boulardii in ulcerative colitis. Eur J Gastroenterol Hepatol. 15: 697—698. http://dx.doi.org/10.1097/00042737-200306000-00017; PMid:12840682

23. Harris MS, Lichtenstein GR. 2011. Review article: delivery and efficacy of topical 5-aminosalicylic acid (mesalazine) therapy in the treatment of ulcerative colitis. Aliment Pharmacol Ther. 33: 996—1009. http://dx.doi.org/10.1111/j.1365-2036.2011.04619.x; PMid:21385194

24. Jakobovits SL, Jewell DP, Travis SP. 2007. Infliximab for the treatment of ulcerative colitis: outcomes in Oxford from 2000 to 2006. Aliment Pharmacol Ther. 25: 1055—1060. http://dx.doi.org/10.1111/j.1365-2036.2007.03300.x; PMid:17439506

25. Lev-Tzion R, Turner D. 2012. Is pediatric IBD treatment different than in adults? Minerva Gastroenterol Dietol. 58: 137—150. PMid:22643596

26. Lichtenstein GR, Kamm MA. 2008. Review article: 5-aminosalicylate formulations for the treatment of ulcerative colitis-methods of comparing release rates and delivery of 5-aminosalicylate to the colonic mucosa. Aliment Pharmacol Ther. 28: 663—673. http://dx.doi.org/10.1111/j.1365-2036.2008.03751.x; PMid:18532992

27. Piodi LP, Ulivieri FM, Cermesoni L et al. 2004. Long-term intermittent treatment with low-dose 5-Aminosalicylic enemas for remission maintenance in ulcerative colitis. Scandinavian Journal of Gastroenterology. 39: 154—157. http://dx.doi.org/10.1080/00365520310008133; PMid:15000277

28. Turner D, Levine A, Escher JC et al. 2012. Management of pediatric ulcerative colitis: joint ECCO and ESPGHAN evidence-based Consensus guidelines. J Pediatr Gastroenterol Nutr. 55(3): 340—61. http://dx.doi.org/10.1097/MPG.0b013e3182662233; PMid:22773060

29. National Institute for Health and Clinical Excellence. Infliximab for acute exacerbations of ulcerative colitis (TA163). London, National Institute for Health and Clinical Excellence (NICE). 2008. http://guidance.nice.org.uk/TA163.

30. Ohkusa T, Kato K, Terao S et al. 2010. Newly developed antibiotic combination therapy for ulcerative colitis: a double-blind placebo-controlled multicenter trial. Am J Gastroenterol. 105: 1820—1829. http://dx.doi.org/10.1038/ajg.2010.84; PMid:20216533

31. Aloi M, D'Arcangelo G, Pofi F et al. 2013. Presenting features and disease course of pediatric ulcerative colitis. J Crohns Colitis. 7: 509—515 (1).

32. Henker J, Muller S, Laass MW et al. 2008. Probiotic Escherichia coli Nissle 1917 (EcN) for successful remission maintenance of ulcerative colitis in children and adolescents: an open-label pilot study. Am J Gastroenterol. 46: 874—875. http://dx.doi.org/10.1055/s-2008-1027463

33. Kamm MA, Lichtenstein GR, Sandborn WJ et al. 2008. Randomised trial of once- or twice-daily MMX mesalazine for maintenance of remission in ulcerative colitis. Gut. 57(7): 893—902. http://dx.doi.org/10.1136/gut.2007.138248; PMid:18272546 PMCid:PMC2564831

34. Razack R, Seidner DL. 2007. Nutrition in inflammatory bowel disease. Curr Opin Gastroenterol. 23: 400—405. http://dx.doi.org/10.1097/MOG.0b013e3281ddb2a3; PMid:17545776

35. Regueiro M, Curtis J, Plevy S. 2006. Infliximab for hospitalized patients with severe ulcerative colitis. J Clin Gastroenterol. 40: 476—81. http://dx.doi.org/10.1097/00004836-200607000-00004; PMid:16825928

36. Turner D, Walsh CM, Steinhart AH et al. 2007. Response to corticosteroids in severe ulcerative colitis: a systematic review of the literature and a meta-regression. Clin Gastroenterol Hepatol. 5: 103—110. http://dx.doi.org/10.1016/j.cgh.2006.09.033; PMid:17142106

37. Turner D, Mack D, Leleiko N et al. 2010. Severe pediatric ulcerative colitis: a prospective multicenter study of outcomes and predictors of response. Gastroenterology. 138: 2282—2291. http://dx.doi.org/10.1016/S0016-5085(10)60132-1http://dx.doi.org/10.1053/j.gastro.2010.02.047; PMid:20193683

38. Aceituno M, Garcia-Planella E, Heredia C et al. 2008. Steroid-refractory ulcerative colitis: predictive factors of response to cyclosporine and validation in an independent cohort. Inflammatory Bowel Diseases. 14(3): 347—352. http://dx.doi.org/10.1002/ibd.20322; PMid:18050296

39. Sutherland L, Macdonald JK. 2006. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst Rev. CD000543. http://dx.doi.org/10.1002/14651858.cd000543.pub2

40. Yasukawa K, Tokuda H, Tun X et al. 2012. The detrimental effect of nitric oxide on tissue is associated with inflammatory events in the vascular endothelium and neutrophils in mice with dextran sodium sulfate-induced colitis. Free Radic Res. 46: 1427—1436. http://dx.doi.org/10.3109/10715762.2012.732698; PMid:22998024

41. Malaty HM, Mehta S, Abraham B et al. 2013. The natural course of inflammatory bowel disease-indeterminate from childhood to adulthood: within a 25 year period. Clin Exp Gastroenterol. 6: 115—121. http://dx.doi.org/10.2147/CEG.S44700; PMid:23901288 PMCid:PMC3726299

42. Van Assche G, Dignass A, Panes JJ et al. 2010. The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: definitions and diagnosis. Crohns Colitis. 4: 17—27. http://dx.doi.org/10.1016/j.crohns.2009.12.003

43. Turner D, Griffiths AM. 2011. Acute severe ulcerative colitis in children: a systematic review. Inflamm Bowel Dis. 17: 440—449. http://dx.doi.org/10.1002/ibd.21383; PMid:20645317

44. Ulcerative colitis: management in adults, children and young people (NICE Clinical Guideline CG166). Arch Dis Child Educ Pract Ed. 2014. 99; 5: 194—197. Published Online First: 12 May 2014.